ImmunityBio

ImmunityBio is a life sciences company that focuses on immunotherapy.
History.
ImmunityBio was founded in 2014 by Dr. Patrick Soon-Shiong.
In April 2020, a product developed by ImmunityBio was rumoured to be a potential SARS-CoV-2 coronavirus vaccine.
On 1 June 2020, the product was selected for inclusion on the Operation Warp Speed subsidy list, in order to fund trials involving non-human primates. The company "hope to receive approval from the Food and Drug Administration to begin an initial safety trial in humans in June 2020."
Covid-19 vaccine.
The ImmunityBio COVID-19 vaccine, codenamed hAd5, is a COVID-19 vaccine developed by the United States-based ImmunityBio.
The BioVac Institute, a state-backed South African vaccine company, plans to use a deal it won to manufacture coronavirus vaccines. The contract with American based ImmunityBio Inc is currently conducting phase 1 vaccine trials in South Africa
ImmunityBio and BioVac plan to distribute the vaccines throughout South Africa and Africa.
Phase I/II.
ImmunityBio Inc is currently conducting phase 1 vaccine trials in The United States and South Africa.